National Cancer Institute Thesaurus

Last uploaded: September 30, 2019
Preferred Name

Fenofibrate

Synonyms

TriCor

fenofibrate

Tricor

Lofibra

Fenofibrate

FENOFIBRATE

Definitions

A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C29047

ALT_DEFINITION

A drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent.

CAS_Registry

49562-28-9

CHEBI_ID

CHEBI:5001

Chemical_Formula

C20H21ClO4

code

C29047

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.

Display_Name

Fenofibrate

FDA_UNII_Code

U202363UOS

FULL_SYN

TriCor

fenofibrate

Tricor

Lofibra

Fenofibrate

FENOFIBRATE

label

Fenofibrate

Legacy_Concept_Name

Fenofibrate

PDQ_Closed_Trial_Search_ID

459750

PDQ_Open_Trial_Search_ID

459750

Preferred_Name

Fenofibrate

prefixIRI

ncit:C29047

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C0033228

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C98150

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.241.081.114.968.500.625 RH-MESH LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D011345 RH-MESH LOOM
http://www.co-ode.org/ontologies/galen#Fenofibrate GALEN LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.355.726.305.625 RH-MESH LOOM
http://purl.bioontology.org/ontology/LNC/LP171398-3 LOINC LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 BIOMODELS LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 GO-PLUS LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 CHEBI LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 CCONT LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 EFO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 DINTO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 GO-PLUS LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 CHEBI LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_5001 NIFSTD LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#10140 OCHV LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000148554 OCVDAE LOOM
http://www.drugbank.ca/drugs/DB01039 FTC LOOM
http://purl.bioontology.org/ontology/UATC/C10AB05 ATC LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.455.426.559.389.115.124.750 RH-MESH LOOM
http://purl.jp/bio/4/id/200906089354123549 IOBC LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.455.426.559.389.657.654.305.625 RH-MESH LOOM
http://purl.bioontology.org/ontology/MESH/D011345 MESH LOOM
http://purl.bioontology.org/ontology/VANDF/4021098 VANDF LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#C0033228 OCHV LOOM
http://purl.bioontology.org/ontology/RCD/bxc.. RCD LOOM
http://purl.bioontology.org/ontology/NDDF/003789 NDDF LOOM
http://purl.bioontology.org/ontology/PDQ/CDR0000459750 PDQ LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.522.223.750 RH-MESH LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/386879008 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000148554 NDFRT LOOM
http://purl.bioontology.org/ontology/RXNORM/8703 RXNORM LOOM
http://stirdf.jst.go.jp/id/200907014115340493 IOBC LOOM